Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Current Investments (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash & Current Investments for 10 consecutive years, with $416.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments rose 39.44% to $416.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $416.7 million, a 39.44% increase, with the full-year FY2024 number at $321.0 million, up 16.24% from a year prior.
  • Cash & Current Investments was $416.7 million for Q3 2025 at Rhythm Pharmaceuticals, up from $155.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $416.7 million in Q3 2025 to a low of $53.9 million in Q1 2024.
  • A 5-year average of $214.9 million and a median of $253.9 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 81.35% in 2023, then surged 484.46% in 2025.
  • Rhythm Pharmaceuticals' Cash & Current Investments stood at $295.2 million in 2021, then grew by 13.02% to $333.6 million in 2022, then fell by 17.22% to $276.2 million in 2023, then grew by 16.24% to $321.0 million in 2024, then rose by 29.81% to $416.7 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Cash & Current Investments are $416.7 million (Q3 2025), $155.4 million (Q2 2025), and $315.0 million (Q1 2025).